Page 400 - Binder2

• Seeds embedded with the genetic instructions for
Factor IX were planted in modular greenhouses.
• Leaves were harvested, freeze-dried, and milled into
capsules.
• Capsules were compounded into patient-specific
dosing regimens and distributed directly through the
local health center.

The outcome?

• Therapy costs dropped by over 90%.
• No cold chain was required.
• Supply was no longer fragile.
• Patients gained consistency, confidence, and
control.

This wasn’t just a medical intervention—it was an
economic and cultural one, reshaping what a rural clinic
could offer its community.

Challenges and Realities

Of course, scaling this model won’t be easy. It requires:

• Regulatory adaptation. Current FDA and EMA
standards are designed around centralized GMP
facilities. Decentralized plant production will
demand new safety, traceability, and validation
frameworks.
• Rethinking intellectual property. Can therapeutic
plants be shared, or will multinational firms license
every leaf? Will communities be allowed to grow
what they co-develop?

398